CordenPharma is investing €80 million at its Caponago, Italy, site, adding a new facility and fill-finish lines to lift sterile injectable capacity to 500 million units/year, backed by shareholder Astorg.
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Houston, Texas.
Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.
US contract research organization Reaction Biology has acquired German contract laboratory Bioassay Labor für biologische Analytik and its wholly owned subsidiary Peptide Specialty Laboratories (PSL).
